Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Jul;40(7):1403-1411.
doi: 10.1097/IAE.0000000000002583.

DIFFERENCE BETWEEN PACHYCHOROID AND NONPACHYCHOROID POLYPOIDAL CHOROIDAL VASCULOPATHY AND THEIR RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY

Yun-Chia Chang  1 , Cheng-Kuo Cheng  1   2
Affiliations
Observational Study

DIFFERENCE BETWEEN PACHYCHOROID AND NONPACHYCHOROID POLYPOIDAL CHOROIDAL VASCULOPATHY AND THEIR RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY

Yun-Chia Chang et al. Retina. 2020 Jul.

Abstract

Purpose: Recent investigations have found a biphasic pattern of choroidal thickness within polypoidal choroidal vasculopathy (PCV) patients. This study aims to investigate the relationship between choroidal thickness and the clinical features of PCV eyes.

Method: We investigated the correlation between various clinical features including subfoveal choroidal thickness (SFCT) and the response to 3-monthly anti-vascular endothelial growth factor (VEGF) treatments in 62 consecutive, treatment-naive PCV patients (66 eyes). After finding out SFCT as the only factor that was correlated with anti-VEGF treatment, we then set up to determine a best cutoff line for SFCT that could be used as a parameter to differentiate PCV patients into pachychoroid and nonpachychoroid groups using the Youden index for best combined specificity and sensitivity. We then compared the demographic features, clinical characteristics, and the response to anti-VEGF between both groups, to determine whether there is a difference between these two groups.

Results: Subfoveal choroidal thickness was the only significant factor for the treatment effect. The SFCT of 267.5 µm is the best cutoff line. The pachychoroid group showed significant younger ages (64.1 ± 9.6 vs. 72.0 ± 8.2, P = 0.004), fewer age-related macular degeneration-like features (50.0 vs. 81.3%, P = 0.027), more central serous chorioretinopathy-like features (typical retinal pigment epithelial mottling [61.1 vs. 16.7%, P = 0.0014] and choroidal vascular hyperpermeability [88.9 vs. 37.5%, P = 0.0002]), and less response to 3-monthly anti-VEGF treatments (27.8 vs. 83.3%, P < 0.0001) as compared to the nonpachychoroid group.

Conclusion: Polypoidal choroidal vasculopathy patients could be subclassified into pachychoroid and nonpachychoroid groups. The pachychoroid subtype of PCV has significantly younger ages, fewer age-related macular degeneration-like features, more central serous chorioretinopathy-like features, and less response to anti-VEGF treatment.

PubMed Disclaimer

References

    1. Wen F, Chen C, Wu D, Li H. Polypoidal choroidal vasculopathy in elderly Chinese patients. Graefe's Archive Clin Exp Ophthalmol 2004;242:625–629.
    1. Liu Y, Wen F, Huang S, et al. Subtype lesions of neovascular age-related macular degeneration in Chinese patients. Graefes Arch Clin Exp Ophthalmol 2007;245:1441–1445.
    1. Chang YC, Wu WC. Polypoidal choroidal vasculopathy in Taiwanese patients. Ophthalmic Surg Lasers Imaging 2009;40:576–581.
    1. Sho K, Takahashi K, Yamada H, et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol 2003;121:1392–1396.
    1. Coscas G, Yamashiro K, Coscas F, et al. Comparison of exudative age-related macular degeneration subtypes in Japanese and French patients: multicenter diagnosis with multimodal imaging. Am J Ophthalmol 2014;158:309–318.e302.

Publication types

Substances

LinkOut - more resources